ArticleJAMA internal medicine2016
Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
Article in JAMA internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Physician associate/assistant contributions to cancer diagnosis in primary care: a rapid systematic review.BMC health services research · 2021Pooled it
- Development and validation of the Artificial Intelligence-Proliferative Vitreoretinopathy (AI-PVR) Insight system for deep learning-based diagnosis and postoperative risk prediction in proliferative vitreoretinopathy using multimodal fundus imaging.Quantitative imaging in medicine and surgery · 2025Article
- Perceived guideline clarity impacts guideline-concordant care for breast cancer screening in women age 40-49.BMC women's health · 2023Article
- Physicians' clinical experience and its association with healthcare quality: a systematised review.BMJ open quality · 2021Article
- Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.Cancer reports (Hoboken, N.J.) · 2021Article
- Factors associated with appropriate and low-value PSA testing.Cancer epidemiology · 2020Article
- Assessment of Clinician Decision-making on Cancer Screening Cessation in Older Adults With Limited Life Expectancy.JAMA network open · 2020Article
- Unrelated Death After Colorectal Cancer Screening: Implications for Improving Colonoscopy Referrals.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2019Article
- Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible overdiagnosis.BMJ open · 2019Article
- Communicating About Stopping Cancer Screening: Comparing Clinicians' and Older Adults' Perspectives.The Gerontologist · 2019Article
- Article
- Exploring factors that might influence primary-care provider discussion of and recommendation for prostate and colon cancer screening.International journal of general medicine · 2018Article
- The State of Men's Health Services in the Veterans Health Administration.Current urology reports · 2017Review
- Prostate cancer screening practices in a large, integrated health system: 2007-2014.BJU international · 2017Article
- Prostate Cancer Screening: A Brief Tool to Incorporate Patient Preferences in a Clinical Encounter.Frontiers in oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
importanceDespite guidelines recommending against prostate-specific antigen (PSA) screening in elderly men with limited life expectancy, PSA screening remains common.
objectiveTo identify clinician characteristics associated with PSA screening rates in older veterans stratified by life expectancy. DESIGN, SETTING, AND
participantsCross-sectional study of 826 286 veterans 65 years or older eligible for PSA screening who had VA laboratory tests performed in 2011 in the VA health care system. MAIN OUTCOMES AND MEASURES: The primary outcome was the percentage of men with a screening PSA test in 2011. Limited life expectancy was defined as age of at least 85 years with Charlson comorbidity score of 1 or greater or age of at least 65 years with Charlson comorbidity score of 4 or greater. Primary predictors were clinician characteristics including degree-training level, specialty, age, and sex. We performed log-linear Poisson regression models for the association between each clinician characteristic and PSA screening stratified by patient life expectancy and adjusted for patient demographics and clinician clustering.
resultsIn 2011, 466 017 (56%) of older veterans received PSA screening, including 39% of the 203 717 men with limited life expectancy. After adjusting for patient demographics, higher PSA screening rates in patients with limited life expectancy was associated with having a clinician who was an older man and was no longer in training. The PSA screening rates ranged from 27% for men with a physician trainee to 42% for men with an attending physician (P < .001); 22% for men with a geriatrician to 82% for men with a urologist as their clinician (P < .001); 29% for men with a clinician 35 years or younger to 41% for those with a clinician 56 years or older (P < .001); and 38% for men with a female clinician older than 55 years vs 43% for men with a male clinician older than 55 years (P < .001). CONCLUSIONS AND RELEVANCE: More than one-third of men with limited life expectancy received PSA screening. Men whose clinician was a physician trainee had substantially lower PSA screening rates than those with an attending physician, nurse practitioner, or physician assistant. Interventions to reduce PSA screening rates in older men with limited life expectancy should be designed and targeted to high-screening clinicians- older male, nontrainee clinicians-for greatest impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.